San Francisco biotechnology companyPrellis Biologicshas successfully raised $8.7 million to advance its holographic 3D bioprinting platform. A Series A investment led by specialist technology capital firmKhosla Ventures, the round was joined by seed contributorsTrue VenturesandIndie Bio.
成功的筹款之前开发的数量elopments at the company including, most recently, pre-clinical experimentation of 3D bioprinted cells within a living animal model. Setting ambitious sights on the creation of full, transplantable organ models Dr. Alex Morgan, Principal at Khosla Ventures, says, “Prellis’ optical technology provides the scaffolding necessary to engineer these larger masses of tissues.”
“与我们的投资在Prellis我们支持n initiative that will ultimately produce a functioning lobe of the lung, or even a kidney, to be used in addressing an enormous unmet global need.”
The journey to viable, artificial vascular tissues
Prellis Biologics was founded in 2016 and is the developer of a laser-based bioprinting method known as holographic 3D printing. This method is capable of producing feature sizes smaller than 0.5 microns. High speeds are also targeted to prevent the deterioration of live cells within the material matrix. At a base level, the technology can cure a liquid to a solid within 5 milliseconds of light exposure.
Prellis’ current aims are to develop holographic 3D printing to a stage where it can quickly and precisely fabricate vascular tissue for organs. In one of the company’s most recent announcements Dr. Melanie Matheu, company co-founder and CEO, explained that the “ultimate goal” is to 3D print “the entire vascular system of akidney in 12 hours or less.”
In a rudimentary step towards this ambitious aim, the company has so far launched its Vascular Tissue Blanks product. Vascular Tissue Blanks are essentially scaffolds used to culture live cells. Recently, vascular tissues made from these scaffolds were transplanted for the first time in a live animal model at Stanford University. Only 200,00 cells, compared to 2 million and more for typical tumor studies, showed capable of achieving full tumor engraftment and vascularization. “A breakthrough like this opens the door to studying rare human tumors and complex human tumor immune system reactions,” explains Dr. Matheu. “It has the potential to significantly reduce overall animal use and speed up drug discovery efforts.”
Khosla’s 3D printing portfolio
The capital investment fund of Indian American billionaire businessman Vinod Khosla, Khosla Ventures is interested in early stage companies in high tech sectors. As such, the company has contributed to the funding of several other 3D printing related companies. In late 2018, the company invested in the$140 million Series Efinancing round for U.S. private aerospace manufacturerRocket Lab. Prior to that, 3D printed composite specialistAREVObenefited from its backing in a$12.5 million financing roundwith two other parties. The fund has alsoinvested in metal 3D printerdeveloperDigital Alloysin the past.
“Khosla Ventures is the perfect investor to support our merging of deep tech and cutting-edge regenerative medicine,” comments Dr. Matheu.
“With this technology in hand, we can begin to ask questions about real 3D cell biology that have never been asked before.”
For all of the latest additive manufacturing business news subscribe to ournewsletter, follow us onTwitter, and like us onFacebook. Find talent for a project, or advance your career in 3D printing – join3D Printing Jobsto apply and advertise.
Featured image shows a microscopic structure for encapsulating cells made via Prellis holographic 3D bioprinting. Image via Prellis Biologics
